Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
8
ALT Quote, Financials, Valuation and Earnings
Last price:
$4.05
Seasonality move
:
-7.97%
Day range:
$4.15 - $4.28
52-week range:
$2.90 - $11.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15,089.22x
P/B ratio:
2.38x
Volume:
2.6M
Avg. volume:
9M
1-year change:
-48.4%
Market cap:
$339M
Revenue:
$20K
EPS (TTM):
-$1.26
Analysts' Opinion
-
Consensus RatingAltimmune has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $17.60, Altimmune has an estimated upside of 321.05% from its current price of $4.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $4.18.
Fair Value
-
According to the consensus of 7 analysts, Altimmune has 321.05% upside to fair value with a price target of $17.60 per share.
ALT vs. S&P 500
-
Over the past 5 trading days, Altimmune has underperformed the S&P 500 by -11.87% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Altimmune does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Altimmune has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Altimmune reported revenues of $5K.
Earnings Growth
-
Altimmune has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Altimmune reported earnings per share of -$0.26.
Enterprise value:
189.2M
EV / Invested capital:
--
Price / LTM sales:
15,089.22x
EV / EBIT:
--
EV / Revenue:
9,460.06x
PEG ratio (5yr expected):
-1.96x
EV / Free cash flow:
-2.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-55.97%
Net Income Margin (TTM):
-451200%
Return On Equity:
-62.28%
Return On Invested Capital:
-62.28%
Operating Margin:
-436300%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -$79K | $410K | $20K | $5K | $5K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$90M | -$88.5M | -$98.2M | -$26.8M | -$21.8M | |
| EBITDA | -$85M | -$92.3M | -$90.8M | -$24.3M | -$20.2M | |
| Diluted EPS | -$1.73 | -$1.61 | -$1.26 | -$0.34 | -$0.26 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $245.2M | $191.1M | $173.1M | $187.5M | $155.3M | |
| Total Assets | $264.3M | $205.7M | $187.1M | $188.4M | $157.3M | |
| Current Liabilities | $9.8M | $19.1M | $15M | $11.3M | $9.8M | |
| Total Liabilities | $17.8M | $20.8M | $19.4M | $15.4M | $15.1M | |
| Total Equity | $246.4M | $184.9M | $167.7M | $172.9M | $142.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$68.5M | -$72.8M | -$80.3M | -$16.4M | -$16.8M | |
| Cash From Investing | -$60.1M | -$39.1M | $6M | -$39.5M | -$5.1M | |
| Cash From Financing | $53.3M | $86.1M | $44.4M | -$261K | $34.1M | |
| Free Cash Flow | -$68.6M | -$72.8M | -$80.3M | -$16.4M | -$16.8M | |
ALT
Sector
Market Cap
$339M
$34.4M
Price % of 52-Week High
37.46%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-11.5%
-1.01%
1-Year Price Total Return
-48.4%
-37.36%
Beta (5-Year)
0.473
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.36
200-day SMA
Sell
Level
$6.38
Bollinger Bands (100)
Sell
Level
4.54 - 6.3
Chaikin Money Flow
Sell
Level
-209.3M
20-day SMA
Sell
Level
$5.12
Relative Strength Index (RSI14)
Sell
Level
39.87
ADX Line
Sell
Level
27.02
Williams %R
Neutral
Level
-39.9061
50-day SMA
Sell
Level
$5.53
MACD (12, 26)
Sell
Level
-0.46
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Neutral
Level
511M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.0113)
Sell
CA Score
(Annual)
Level (-1.0434)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (10.0738)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Stock Forecast FAQ
In the current month, ALT has received 5 Buy ratings 1 Hold ratings, and 1 Sell ratings. The ALT average analyst price target in the past 3 months is $17.60.
-
Where Will Altimmune Stock Be In 1 Year?
According to analysts, the consensus estimate is that Altimmune share price will rise to $17.60 per share over the next 12 months.
-
What Do Analysts Say About Altimmune?
Analysts are divided on their view about Altimmune share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Altimmune is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Altimmune's Price Target?
The price target for Altimmune over the next 1-year time period is forecast to be $17.60 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ALT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Altimmune is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALT?
You can purchase shares of Altimmune via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Altimmune shares.
-
What Is The Altimmune Share Price Today?
Altimmune was last trading at $4.05 per share. This represents the most recent stock quote for Altimmune. Yesterday, Altimmune closed at $4.18 per share.
-
How To Buy Altimmune Stock Online?
In order to purchase Altimmune stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
